â– LECTURE OVERVIEW: Cervical cancer develops via a predictable progression driven by chronic infection with high-risk strains of Human Papillomavirus (HPV).
â– THE MOLECULAR PATHWAYS:
1. High-Risk Strains: Primarily HPV strains 16 and 18.
2. Genomic Integration: The virus enters basal epithelial cells, integrating its circular DNA into the host genome, which triggers the overexpression of viral oncogenes E6 and E7.
3. E6 (p53 degradation): The E6 protein binds and targets the p53 tumor suppressor for ubiquitin-mediated proteasomal degradation, bypassing cell cycle arrest and apoptosis in response to DNA damage.
4. E7 (Rb inactivation): The E7 protein binds and hyperphosphorylates the Retinoblastoma (Rb) protein, releasing the E2F transcription factor. Constant E2F activity drives the cell into S-phase replication.
5. Transformation Zone: This neoplastic transformation occurs selectively at the squamocolumnar junction (transformation zone) of the cervix, where columnar epithelium undergoes squamous metaplasia.
â– BIOCHEMICAL MECHANISMS:
At the molecular level, enzyme kinetics govern reaction rates. Competitive inhibitors raise apparent Michaelis constants without changing maximum speed, whereas noncompetitive inhibitors decrease maximum speed directly.
â– ACUTE TOXICOLOGICAL PROFILE:
High cumulative chemical exposure or accidental overdose triggers systemic receptor overload, cellular injury, and metabolic acidosis.
[HY-BOARD-1170]
🌟 Dynamic Clinical Key:
Cervical cancer is highly preventable via Pap smear screening (which cytologically identifies dysplasia before it becomes invasive cancer) and the recombinant HPV vaccine, which target major high-risk viral capsid antigens. Focus on rate-limiting regulatory steps for pharmacological design. Immediate administration of physiological charcoal or specific receptor antagonists is lifesaving.